We are pioneering research, development and the provision of access to commercially effective and affordable cannabinoid-based medicines specifically for treating patients suffering from cancer-related pain in the UK.
We launched the first Real-World Evidence (RWE) peer-reviewed clinical trial in this domain. Supported by our already established & highly reputable Clinical Advisory Board.
We have received a number of highly sought-after endorsements and have partnerships with a number of leading oncology research centres across the UK, more information on these can be found under About Us.
Access the CBD Science Investor Portal. Here you can find all the documents you may require for due diligence.
The UK legal cannabis market is forecast to reach €1.5 billion by 2026 (Prohibition Partners, 2021).
Comparable companies have already shown exceptional value and are trading at up to 80 times revenue.
